CLB
ACHAT TOTAL: 5 000 titres (~53 900,00 $ US)
- Insiders
- Bruno Lawrence
- Total bought
- $53,900
- Total sold
- —
- Last activity
- 2026-07-31
- Last synced
-
2026-08-06 10:27:36
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Neutral signal Scored 2026-08-05
CLB shows adequate liquidity (75) and moderate fundamental stability, but stagnant top-line growth, shrinking headcount, and zero R&D investment structurally cap upside potential.
The first sentence of the analysis written for CLB on 2026-08-05 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 17.9% | 16.9% | 18.4% | 16.1% | 17.8% | |
| Ebit Margin | 10.7% | 11.2% | 10.7% | 8.5% | 9.6% | |
| Ebitda Margin | 13.5% | 14.0% | 13.8% | 12.0% | 13.6% | |
| Operating Profit Margin | 9.6% | 11.2% | 10.7% | 8.5% | 9.6% | |
| Pretax Profit Margin | 8.7% | 8.8% | 8.1% | 6.1% | 7.7% | |
| Continuous Operations Profit Margin | 5.8% | 6.1% | 7.3% | 4.0% | 4.3% | |
| Net Profit Margin | 5.6% | 6.0% | 7.2% | 4.0% | 4.2% | |
| Bottom Line Profit Margin | 5.6% | 6.0% | 7.2% | 4.0% | 4.2% | |
| Current Ratio | 2.025 | 2.322 | 2.533 | 2.053 | 2.083 | |
| Quick Ratio | 1.511 | 1.713 | 1.719 | 1.467 | 1.582 | |
| Solvency Ratio | 0.142 | 0.139 | 0.147 | 0.094 | 0.091 | |
| Cash Ratio | 0.214 | 0.196 | 0.172 | 0.150 | 0.195 | |
| Price To Earnings Ratio | 23.574 | 25.836 | 22.354 | 48.262 | 51.884 | |
| Price To Earnings Growth Ratio | 15.794 | -1.701 | 0.254 | -20.753 | -0.433 | |
| Forward Price To Earnings Growth Ratio | 15.794 | -1.701 | 0.254 | -20.753 | -0.433 | |
| Price To Earnings Diluted Ratio | 23.574 | 26.227 | 22.935 | 48.262 | 53.119 | |
| Price To Earnings Diluted Growth Ratio | 7.779 | -1.836 | 0.275 | 0.000 | -0.445 | |
| Price To Book Ratio | 2.802 | 3.221 | 3.667 | 5.097 | 6.561 | |
| Price To Sales Ratio | 1.416 | 1.550 | 1.617 | 1.918 | 2.183 | |
| Price To Free Cash Flow Ratio | 33.438 | 18.722 | 58.017 | 63.717 | 44.551 | |
| Price To Operating Cash Flow Ratio | 20.129 | 14.396 | 33.258 | 37.634 | 28.061 | |
| Debt To Assets Ratio | 0.281 | 0.305 | 0.367 | 0.385 | 0.431 | |
| Debt To Equity Ratio | 0.617 | 0.715 | 0.958 | 1.207 | 1.600 | |
| Debt To Capital Ratio | 0.381 | 0.417 | 0.489 | 0.547 | 0.615 | |
| Long Term Debt To Capital Ratio | 0.293 | 0.334 | 0.421 | 0.483 | 0.547 | |
| Financial Leverage Ratio | 2.196 | 2.343 | 2.608 | 3.139 | 3.713 | |
| Working Capital Turnover Ratio | 4.431 | 3.968 | 4.185 | 4.735 | 5.394 | |
| Operating Cash Flow Ratio | 0.349 | 0.578 | 0.281 | 0.242 | 0.403 | |
| Operating Cash Flow Sales Ratio | 0.070 | 0.108 | 0.049 | 0.051 | 0.078 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.602 | 0.769 | 0.573 | 0.591 | 0.630 | |
| Debt Service Coverage Ratio | 5.260 | 4.808 | 4.932 | 4.182 | 5.232 | |
| Interest Coverage Ratio | 4.776 | 4.734 | 4.069 | 3.589 | 4.946 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 0.226 | 0.313 | 0.115 | 0.112 | 0.146 | |
| Capital Expenditure Coverage Ratio | 2.512 | 4.328 | 2.343 | 2.443 | 2.702 | |
| Dividend Paid And Capex Coverage Ratio | 2.230 | 3.783 | 1.992 | 2.068 | 2.379 | |
| Dividend Payout Ratio | 0.063 | 0.060 | 0.051 | 0.095 | 0.093 | |
| Enterprise Value Multiple | 12.468 | 13.233 | 14.550 | 19.531 | 19.741 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 17.9% | ▲1.0% | ▲0.5% |
| Ebit Margin | 10.7% | ▼-0.4% | ▲0.6% |
| Ebitda Margin | 13.5% | ▼-0.5% | ▲0.1% |
| Operating Profit Margin | 9.6% | ▼-1.6% | ▼-0.3% |
| Pretax Profit Margin | 8.7% | ▼-0.1% | ▲0.8% |
| Continuous Operations Profit Margin | 5.8% | ▼-0.4% | ▲0.3% |
| Net Profit Margin | 5.6% | ▼-0.4% | ▲0.2% |
| Bottom Line Profit Margin | 5.6% | ▼-0.4% | ▲0.2% |
| Current Ratio | 2.025 | ▼-0.297 | ▼-0.178 |
| Quick Ratio | 1.511 | ▼-0.203 | ▼-0.087 |
| Solvency Ratio | 0.142 | ▲0.003 | ▲0.019 |
| Cash Ratio | 0.214 | ▲0.018 | ▲0.029 |
| Price To Earnings Ratio | 23.573 | ▼-2.262 | ▼-10.808 |
| Price To Earnings Growth Ratio | 15.794 | ▲17.495 | ▲17.162 |
| Forward Price To Earnings Growth Ratio | 15.794 | ▲17.495 | ▲17.162 |
| Price To Earnings Diluted Ratio | 23.573 | ▼-2.654 | ▼-11.250 |
| Price To Earnings Diluted Growth Ratio | 7.779 | ▲9.615 | ▲6.625 |
| Price To Book Ratio | 2.802 | ▼-0.419 | ▼-1.467 |
| Price To Sales Ratio | 1.416 | ▼-0.134 | ▼-0.321 |
| Price To Free Cash Flow Ratio | 33.438 | ▲14.716 | ▼-10.251 |
| Price To Operating Cash Flow Ratio | 20.129 | ▲5.732 | ▼-6.567 |
| Debt To Assets Ratio | 0.281 | ▼-0.024 | ▼-0.073 |
| Debt To Equity Ratio | 0.617 | ▼-0.098 | ▼-0.403 |
| Debt To Capital Ratio | 0.381 | ▼-0.035 | ▼-0.108 |
| Long Term Debt To Capital Ratio | 0.293 | ▼-0.041 | ▼-0.122 |
| Financial Leverage Ratio | 2.196 | ▼-0.147 | ▼-0.604 |
| Working Capital Turnover Ratio | 4.431 | ▲0.463 | ▼-0.112 |
| Operating Cash Flow Ratio | 0.349 | ▼-0.229 | ▼-0.021 |
| Operating Cash Flow Sales Ratio | 0.070 | ▼-0.037 | ▼-0.001 |
| Free Cash Flow Operating Cash Flow Ratio | 0.602 | ▼-0.167 | ▼-0.031 |
| Debt Service Coverage Ratio | 5.260 | ▲0.452 | ▲0.377 |
| Interest Coverage Ratio | 4.776 | ▲0.042 | ▲0.353 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | 0.226 | ▼-0.087 | ▲0.043 |
| Capital Expenditure Coverage Ratio | 2.512 | ▼-1.816 | ▼-0.353 |
| Dividend Paid And Capex Coverage Ratio | 2.230 | ▼-1.554 | ▼-0.261 |
| Dividend Payout Ratio | 0.063 | ▲0.003 | ▼-0.009 |
| Enterprise Value Multiple | 12.468 | ▼-0.765 | ▼-3.436 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $745.4M | $811.8M | $824.4M | $939.2M | $1.03B | |
| Enterprise value | $886.7M | $972.8M | $1.02B | $1.15B | $1.26B | |
| EV / Sales | 1.68x | 1.86x | 2.01x | 2.34x | 2.68x | |
| EV / Op. cash flow | 23.95x | 17.25x | 41.34x | 45.93x | 34.42x | |
| EV / Free cash flow | 39.78x | 22.43x | 72.11x | 77.76x | 54.65x | |
| EV / EBITDA | 12.47x | 13.23x | 14.55x | 19.53x | 19.74x | |
| Net debt / EBITDA | 1.99x | 2.19x | 2.84x | 3.53x | 3.65x | |
| Current ratio | 2.02x | 2.32x | 2.53x | 2.05x | 2.08x | |
| Income quality | 1.22x | 1.75x | 0.67x | 1.27x | 1.81x | |
| Graham number | $9 | $9 | $9 | $6 | $6 | |
| Graham net-net | -$4 | -$4 | -$5 | -$6 | -$7 | |
| Tax burden | 64.6% | 68.0% | 89.0% | 64.9% | 54.6% | |
| Interest burden | 81.3% | 78.9% | 75.4% | 72.1% | 79.8% | |
| Working capital | $108.7M | $129.0M | $135.0M | $108.6M | $98.3M | |
| Invested capital | $375.4M | $388.4M | $394.9M | $372.9M | $378.2M | |
| Return on assets | 5.1% | 5.3% | 6.3% | 3.4% | 3.4% | |
| Operating ROA | 8.6% | 10.0% | 9.4% | 7.2% | 7.9% | |
| Return on tangible assets | 6.3% | 6.5% | 7.6% | 4.1% | 4.2% | |
| Return on equity | 11.2% | 12.5% | 16.3% | 10.6% | 12.6% | |
| Return on invested capital | 6.8% | 8.1% | 9.7% | 5.6% | 5.0% | |
| Return on capital employed | 10.6% | 11.9% | 11.0% | 8.7% | 9.2% | |
| Earnings yield | 4.0% | 3.9% | 4.4% | 2.1% | 1.9% | |
| Free cash flow yield | 3.0% | 5.3% | 1.7% | 1.6% | 2.2% | |
| Capex / Op. cash flow | 39.8% | 23.1% | 42.7% | 40.9% | 37.0% | |
| Capex / Depreciation | 100.6% | 87.1% | 67.0% | 59.5% | 73.1% | |
| Capex / Sales | 2.8% | 2.5% | 2.1% | 2.1% | 2.9% | |
| SG&A / Sales | 8.4% | 7.4% | 7.6% | 7.8% | 9.4% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 1.4% | 0.7% | 2.7% | 1.6% | 4.1% | |
| Intangibles / Total assets | 19.3% | 17.9% | 18.1% | 18.5% | 18.5% | |
| Days sales outstanding | 84d | 89d | 88d | 86d | 83d | |
| Days payables outstanding | 31d | 29d | 29d | 41d | 28d | |
| Operating cycle | 130d | 139d | 151d | 139d | 126d | |
| Cash conversion cycle | 98d | 110d | 122d | 99d | 98d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-8.2%EV / Sales ▼-9.3%EV / EBITDA ▼-5.8%EV / Op. cash flow ▲+6.694Earnings yield ▲+0.001Graham number ▲+0.065
Profitability
Return on equity ▼-0.013Return on assets ▼-0.002Return on invested capital ▼-0.013Return on capital employed ▼-0.013Operating ROA ▼-0.014Income quality ▼-0.535Tax burden ▼-0.033
Efficiency
Days sales outstanding ▼-4.996Days payables outstanding ▲+2.519Operating cycle ▼-8.766Cash conversion cycle ▼-11.285Capex / Sales ▲+0.003R&D / Sales n/a
Balance-sheet strength
Current ratio ▼-0.297Net debt / EBITDA ▼-0.203Working capital ▼-20370000.000Invested capital ▼-13069000.000Intangibles / Total assets ▲+0.014
Change over 5 years
Valuation
Market cap ▼-27.4%EV / Sales ▼-37.1%EV / EBITDA ▼-36.8%EV / Op. cash flow ▼-10.474Earnings yield ▲+0.021Graham number ▲+3.334
Profitability
Return on equity ▼-0.015Return on assets ▲+0.017Return on invested capital ▲+0.018Return on capital employed ▲+0.013Operating ROA ▲+0.007Income quality ▼-0.591Tax burden ▲+0.100
Efficiency
Days sales outstanding ▲+0.891Days payables outstanding ▲+3.398Operating cycle ▲+3.985Cash conversion cycle ▲+0.587Capex / Sales ▼-0.001R&D / Sales n/a
Balance-sheet strength
Current ratio ▼-0.058Net debt / EBITDA ▼-1.659Working capital ▲+10377000.000Invested capital ▼-2846000.000Intangibles / Total assets ▲+0.008
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2018-12-10 | Thomas J. Rooney | Sale (Full) | $15,001 - $50,000 |
Recent news
- 2026-07-31 Is CLB Stock Attractive After Its Sharp Selloff and Mixed Q2 Results? Core Laboratories stock looks cheaper after a 47.1% six-month selloff, but falling earnings and geopolitical pressure keep the near-term case cautious.
- 2026-07-31 Core Laboratories Q2 Earnings Beat Estimates, Decline Y/Y CLB''s Q2 earnings top estimates despite lower revenues and profit as Production Enhancement strength offsets Reservoir Description weakness.
- 2026-07-31 Core Laboratories Q2 Earnings Call Highlights Core Laboratories NYSE: CLB reported second-quarter 2026 revenue of $124.6 million, up more than 2% from the prior quarter but down 4% from a year earlier, as stronger completion-product sales partly offset disruptions to its service business from conflicts in the Middle East and Russia-Ukraine.
- 2026-07-30 Core Laboratories Inc. (CLB) Q2 2026 Earnings Call Transcript Core Laboratories Inc. (CLB) Q2 2026 Earnings Call Transcript
- 2026-07-29 Core Laboratories (CLB) Q2 Earnings Surpass Estimates Core Laboratories (CLB) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of $0.08 per share. This compares to earnings of $0.19 per share a year ago.
- 2026-07-29 CORE LAB REPORTS SECOND QUARTER 2026 RESULTS REVENUE OF $ 124.6 MILLION, UP 2% SEQUENTIALLY AND DOWN 4% YEAR-OVER-YEAR OPERATING INCOME OF $ 9.2 MILLION; EX-ITEMS, $9.4 MILLION, UP 42% SEQUENTIALLY AND DOWN 36% YEAR-OVER-YEAR GAAP EARNINGS PER SHARE OF $0.13; EPS EX-ITEMS OF $0.11, UP 85% SEQUENTIALLY AND DOWN 42% YEAR-OVER-YEAR FREE CASH FLOW OF $ 3.1 MILLION COMPANY REPURCHASED 214,712 SHARES OF COMMON STOCK, FOR $2.7 MILLION AGGREGATE PURCHASE PRICE COMPANY ANNOUNCES Q3 2026 QUARTERLY DIVIDEND HOUSTON, July 29, 2026 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core," "Core Lab," or the "Company") reported second quarter 2026 revenue of $124,600,000. Core''s operating income was $9,200,000, with earnings per diluted share ("EPS") of $0.13, all in accordance with U.S. generally accepted accounting principles ("GAAP").
- 2026-07-23 Ariel Small/Mid Cap Value Q2 2026 Portfolio Activity The Ariel Small/Mid Cap Value Composite rose +15.08% gross of fees (+14.95% net of fees) in the quarter, falling short of both the Russell 2500 Value Index''s +18.50% return and the +20.26% gain posted by the Russell 2500 Index. Live entertainment, media, and technology company, Sphere Entertainment Co. was the top contributor during the quarter on solid earnings and improving operating fundamentals. Shares of Prestige Consumer Healthcare moved lower following disappointing earnings, driven primarily by ongoing supply constraints in its eye care segment and extended lead times in the Middle East.
- 2026-07-23 What''s in Store for Core Laboratories Stock in Q2 Earnings? CLB''s Q2 may reflect resilient international activity and tariff insulation, but weaker reservoir description results and higher costs could weigh.
- 2026-07-22 Earnings Preview: Core Laboratories (CLB) Q2 Earnings Expected to Decline Core Laboratories (CLB) doesn''t possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 2026-07-20 Core Stock Down 39% in 6 Months: Should You Hold or Sell Now? CLB struggles with ongoing headwinds from lower completion activity, operational disruptions, inflationary costs, weaker margins and projected earnings decline in 2026.